Richard Conway RichardPAConway
3 years 11 months ago
Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reactive arthritis, 0.75 sero-RA, 0.5 PsA. Promising but not there yet. @RheumNow #ACR22 Abstr#0531 https://t.co/clLR0V33WJ https://t.co/7Hts9gtkW9
Dr. Rachel Tate uptoTate
3 years 11 months ago
Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
Richard Conway RichardPAConway
3 years 11 months ago
Gomez et al. Predictors renal flare in SLE. Adjusted models - low C3, low albumin, proteinuria. @RheumNow #ACR22 Abstr#0540 https://t.co/POfeAa9Ao9 https://t.co/a3JkSP1MkX
Eric Dein ericdeinmd
3 years 11 months ago
In-person meetings are tough. Virtual meetings are tough. But hybrid meetings are logistical nightmares
Would've liked better WiFi and a live poster hall, but a HUGE credit to @ACRheum on planning a great #ACR22 hybrid meeting. Really amazing job
@RheumNow
Dr. Antoni Chan synovialjoints
3 years 11 months ago
Getting to know the COVID-19 drugs:
◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld)
◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV)
Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Dr. John Cush RheumNow
3 years 11 months ago
Show us how you ACR! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/aAUyhmrLPW
The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation. Framing it another way, there were better outcomes in pre-RA because we were actually treating RA as it emerged with a proven effective treatment. It is
Julian Segan JulianSegan
3 years 11 months ago
Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database.
Residual pain and harm minimisation still areas of need.
@RheumNow #ACR22 ABST0925
https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY
Dr. Antoni Chan synovialjoints
3 years 11 months ago
JAK and TYK-2 inhibitors and indications in SpA:
● Tofacitinib ➣ Pan JAKi (AS, PsA)
● Baricitinib ➣ JAK1,2
● Upadacitinib ➣ JAK1 (AxSpA, PsA)
● Deucravacitinib ➣ TYK2 (PsA)
Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
sheila RHEUMarampa
3 years 11 months ago
Differences between #uveitis pattern in AS vs. PsA and IBD 👇
This is always asked to our rheum fellows during Kelley's hour 🤓
#ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
Richard Conway RichardPAConway
3 years 11 months ago
Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% women at 10 years. 40% Black, 38% Hispanic, 40% Asian, 23% White. @RheumNow #ACR22 Abstr#0538 https://t.co/Nbx16jZAN7 https://t.co/BEnAtbcIHt
Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally?
